

Claims

1. Colostrinin for use as a medicament.
- 5 2. Colostrinin for use as a medicament for humans.
3. Colostrinin for use in the treatment of chronic disorders of the central nervous system.
- 10 4. Colostrinin according to claim 3, for use in the treatment of neurological disorders and/or mental disorders.
- 15 5. Colostrinin according to claim 3, for use in the treatment of dementia and/or neurodegenerative diseases.
- 20 6. Colostrinin according to claim 3, for use in the treatment of Alzheimer's disease and/or motor neurone disease.
7. Colostrinin according to claim 3, for use in the treatment of psychosis and/or neurosis.
8. Colostrinin for use in the treatment of chronic disorders of the immune system.
- 25 9. Colostrinin for use in the treatment of chronic disorders of the immune system in humans.
- 30 10. Colostrinin according to claim 9 or 10, for use in the treatment of diseases with a bacterial and viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

-23-

11. Colostrinin according to claim 9, 10 or 11, for use in the treatment of chronic bacterial and/or viral infections.

12. Colostrinin according to any preceding claim, wherein said Colostrinin is derived from a non-ovine source.

13. The use of Colostrinin in the manufacture of a medicament for the treatment of chronic disorders of the central nervous system.

14. The use according to claim 13, for the treatment of neurological disorders and/or mental disorders.

15. The use according to claim 14, for the treatment of dementia and/or neurodegenerative diseases.

16. The use according to claim 14, for the treatment of for use of Alzheimer's disease and/or motor neurone disease.

17. The use according to claim 14, for the treatment of psychosis and/or neurosis.

18. The use of Colostrinin in the manufacture of a medicament for the treatment of chronic disorders of the immune system.

19. The use of Colostrinin in the manufacture of a medicament for the treatment of chronic disorders of the immune system in humans.

20. The use according to claim 18 or 19, for the treatment of diseases with a bacterial and viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

~~Sub 18~~ 21. The use according to claim 18, 19 or 20, for the treatment of bacterial and/or viral infections. ~~2~~

22. The use according to any one of claims 18 to 21, wherein said
5 Colostrinin is non-ovine Colostrinin.

23. A method of treating disorders of the central nervous system and/or of the immune system using Colostrinin. ~~3~~

~~Sub 81~~ 24. A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a predetermined amount of a composition containing Colostrinin to a patient for a predetermined period of time. ~~10~~

~~Sub 13~~ 25. A method according to claim 24, wherein the patient is a human patient. ~~15~~

26. A method according to claim 23, 24 or 25, wherein the Colostrinin is non-ovine Colostrinin. ~~20~~

27. A method according to any one of claims 23 to 26, comprising wherein said predetermined amount of Colostrinin is in the range of about 25 to 2000 micrograms.

~~Sub FS1~~ 28. A method according to claim 27, comprising a cycle of administering 25 to 2000 micrograms of Colostrinin each day to a patient for a first period, followed by a second period when no Colostrinin is administered. ~~25~~

29. A method according to claim 28, wherein the first period is in the range of about 2 to 4 weeks, and the second period is in the range of about 2 to
30

-25-

Sub F5
100. 5 weeks.

Sub A4

30. A method according to claim 28 or 29, wherein the cycle is repeated at least once.

5

31. A pharmaceutical composition comprising a preselected amount of Colostrinin in combination with a physiologically acceptable carrier.

32. A composition according to claim 31, wherein the Colostrinin is non-ovine Colostrinin.

33. A composition according to claim 31 or 32, in a form suitable for injection.

34. A composition according to claim 31 or 32, in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for absorption in the alimentary canal.

35. A composition according to any one of claims 31 to 34, in the form of a tablet, lozenge, gel, patch or plaster.

36. A composition according to any one of claims 31 to 35, comprising 25 to 1000 micrograms of Colostrinin.

37. A composition according to any one of claims 31 to 35 comprising 50 to 100 micrograms of Colostrinin.

38. The use of Colostrinin as a dietary supplement.

39. The use of Colostrinin as a dietary supplement for babies, small

Rule 38
124 39.

30 39
40.

Sub F8
10
664260-5436928
052499

children, adults who have been subjected to chemotherapy and/or adults who have suffered from anorexia, or weight loss due to chronic disease.

40
41. ~~Sub 34~~ A dietary supplement comprising an orally ingestible combination of Colostrinin in combination with a physiologically acceptable carrier.

41
42. Colostrinin for use in the stimulation and/or modulation of the immune system of mammals.

42
43. Colostrinin for use in the stimulation and/or modulation of the immune system of humans.

43
44. The use of Colostrinin in the manufacture of a medicament for use in the stimulation and/or modulation of the immune system of mammals.

44
44. The use of Colostrinin in the manufacture of a medicament for use in the stimulation and/or modulation of the immune system of humans.

45
45. Colostrinin for use as a prophylactic medicament.

45
46. Colostrinin for use as a prophylactic medicament for humans, to prevent or inhibit the development of Alzheimer's disease.

46
47. The use of Colostrinin in the manufacture of a prophylactic medicament for humans, to prevent or inhibit the development of Alzheimer's disease.

47
48. A method of preparing Colostrinin from mammalian colostrum, comprising

Rule 124

00269945
54869260

Rule 124
2044

Sub 8

Sub 25

Sub 30

-27-

- Rule 126
- 5
- (1) Removing lipids and the majority of proteins from the colostrum;
 - (2) separating Colostrinin bound to immunoglobulin from the colostrum; and
 - (3) Separating the Colostrinin from the immunoglobulin, and purifying the Colostrinin.

48
49.

10 A method according to claim 48, wherein in step (1) the lipids are removed by centrifuging and the proteins are removed by pH lowering; in step (2) the Colostrinin bound to immunoglobulin is removed from the colostrum by processing the fraction formed after the removal of lipids and proteins by ion exchange chromatography, eluting with phosphate buffered saline and collecting a fraction containing Colostrinin bound to immunoglobulin; and step (3) comprises separating Colostrinin from the immunoglobulin by sieving chromatography, and further purifying the Colostrinin by de-salting the fraction below 30,000 Daltons molecular weight and introducing antibodies to immunoglobulins and thereby remove this class of proteins to obtain the final product.

20 49
50.

A method of making a pharmaceutical composition comprising combining Colostrinin with a physiologically acceptable carrier, and forming said mixture into a form in which it can be administered to a patient.

50

51.

25

A nanopeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro for use as a medicament.

51

52.

The use of a nanopeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro in the manufacture of a medicament for treating chronic disorders of the immune system in humans.

30

Rule 124
52
53. The use of a nanopeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro in the manufacture of a medicament for treating chronic disorders of the central nervous system.

54
54. A pharmaceutical composition comprising a nanopeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro in combination with a physiologically acceptable carrier.

5A
55. A method of making a pharmaceutical composition comprising combining a nanopeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro with a physiologically acceptable carrier, and forming said mixture into a form in which it can be administered to a patient.

add
27 & 28

064260-54869260